The regulatory downgrade significantly increases binary risk around the August 2026 data readout. Traders should monitor for any additional FDA communications and prepare for high volatility upon results. Without a validated endpoint, the path to approval is uncertain.
LGVN drugs
LGVN drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 11 $0.8380entry
- T+1 · 6mo ago 0.00%α +0.14% · $0.8380
- T+5 · 6mo ago −19.33%α −19.25% · $0.6760
- T+20 · 5mo ago −7.76%α −7.45% · $0.7730
- T+60 · 3mo ago −13.23%α −17.63% · $0.7271
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Longeveron disclosed that the FDA rejected the primary endpoint (RVEF) of its Phase 2b ELPIS II trial for HLHS, and the FDA no longer considers the trial 'pivotal.' Top-line results are still expected in August 2026. This is a material regulatory setback for a micro-cap biotech with no approved products.
Key Facts
- FDA stated primary endpoint (RVEF) is not appropriate to demonstrate efficacy
- FDA no longer refers to ELPIS II as a pivotal trial
- FDA willing to discuss results after trial completion
- Top-line results expected August 2026
- Company intends to submit a Sponsor Statistical Analysis Plan with composite endpoint
Financial Impact
No financial figures provided; market cap ~$20M
Risk Factors
- Failed or inconclusive top-line results could render the program worthless
- No agreed-upon primary endpoint may delay or prevent BLA filing
- Potential need for additional costly trials or capital raise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-053902 |
| Document: ea028985301ex99-1.htm | 0001213900-26-053902 |
| Document: 0001213900-26-053902-index-headers.html | 0001213900-26-053902 |
| Document: 0001213900-26-053902-index.html | 0001213900-26-053902 |
| Document: 0001213900-26-053902.txt | 0001213900-26-053902 |
Track record
22 reports on LGVN
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
- Nov 12, 20264d ago 8-K Bearish 7/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
- Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
- Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
- Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
- Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers